- Home
- QIPT vs ENTX Comparison
QIPT vs ENTX Comparison
Compare QIPT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- ENTX
- Stock Information
- Founded
- QIPT 1993
- ENTX 2010
- Country
- QIPT United States
- ENTX Israel
- Employees
- QIPT N/A
- ENTX N/A
- Industry
- QIPT
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QIPT
- ENTX Health Care
- Exchange
- QIPT Nasdaq
- ENTX Nasdaq
- Market Cap
- QIPT 92.2M
- ENTX 104.0M
- IPO Year
- QIPT N/A
- ENTX 2018
- Fundamental
- Price
- QIPT $1.41
- ENTX $2.03
- Analyst Decision
- QIPT Buy
- ENTX Strong Buy
- Analyst Count
- QIPT 2
- ENTX 1
- Target Price
- QIPT $2.85
- ENTX $10.00
- AVG Volume (30 Days)
- QIPT 154.7K
- ENTX 45.1K
- Earning Date
- QIPT 05-12-2025
- ENTX 05-09-2025
- Dividend Yield
- QIPT N/A
- ENTX N/A
- EPS Growth
- QIPT N/A
- ENTX N/A
- EPS
- QIPT N/A
- ENTX N/A
- Revenue
- QIPT $240,848,000.00
- ENTX $223,000.00
- Revenue This Year
- QIPT $3.35
- ENTX N/A
- Revenue Next Year
- QIPT $5.39
- ENTX N/A
- P/E Ratio
- QIPT N/A
- ENTX N/A
- Revenue Growth
- QIPT N/A
- ENTX N/A
- 52 Week Low
- QIPT $1.86
- ENTX $1.41
- 52 Week High
- QIPT $4.17
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- QIPT 19.52
- ENTX 48.27
- Support Level
- QIPT $2.07
- ENTX $1.84
- Resistance Level
- QIPT $2.24
- ENTX $2.24
- Average True Range (ATR)
- QIPT 0.13
- ENTX 0.15
- MACD
- QIPT -0.07
- ENTX -0.04
- Stochastic Oscillator
- QIPT 6.67
- ENTX 31.32
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.